# Management and Prognosis of Patients with Mild Traumatic Brain Injury: A Narrative Review

**Authors:** Mayank Gupta, Sara Khan, Samantha Bunk, Anand Patil, Joan Stilling, Jaspal Singh, Sudhir Diwan, Michael Schatman, Anushka Bajaj, Alaa Abd-Elsayed, Steven Kosa

PMC · DOI: 10.3390/brainsci16030273 · Brain Sciences · 2026-02-28

## TL;DR

This review discusses how various factors affect recovery and management in patients with mild traumatic brain injuries.

## Contribution

The paper synthesizes current knowledge on diagnostic criteria, management, and prognostic factors for mild traumatic brain injuries.

## Key findings

- Poor prognostic factors include injury-related, patient-related, and psychosocial factors.
- Current treatment includes rest, medication, cognitive therapy, and physical therapy.
- Diagnostic criteria overlap with indicators of poor prognosis.

## Abstract

What are the main findings?
Despite mild traumatic brain injuries having a set diagnostic criterion, several poor prognostic factors greatly influence recovery timelines.These prognostic factors include injury-related factors, patient-related factors, and contextual psychosocial factors.

Despite mild traumatic brain injuries having a set diagnostic criterion, several poor prognostic factors greatly influence recovery timelines.

These prognostic factors include injury-related factors, patient-related factors, and contextual psychosocial factors.

What are the implications of the main findings?
The poor prognostic factors should be taken into consideration when treating patients with mild traumatic brain injuries.Approach to mild traumatic brain injuries should be approached with patient-centered management efforts to manage care adequately.

The poor prognostic factors should be taken into consideration when treating patients with mild traumatic brain injuries.

Approach to mild traumatic brain injuries should be approached with patient-centered management efforts to manage care adequately.

Background/Objectives: Mild traumatic brain injury (mTBI) is the most common subtype of traumatic brain injury, where patients experience a multitude of symptoms from headaches to memory loss and mood changes. Consequently, there are known poor prognostic factors for mTBI that can impede recovery and alter management courses. This narrative review aims to synthesize and provide a critical assessment of the current diagnostic criteria, management, and prognostic factors for mTBI to inform practice guidelines. Methods: This study adopts a patient-centered approach, focusing on treating presenting symptoms and referring patients to specialists for abnormal exam findings as needed. These findings are based on a narrative review of existing literature and the medical opinions of experts in neurology, physical medicine and rehabilitation, and pain medicine. The evidence supports that there are patient-related, injury-related, and contextual psychosocial factors that further complicate the long-term prognosis and management of mTBI. Conclusions: mTBI is defined by a set of diagnostic criteria: post-traumatic amnesia (PTA) lasting no longer than 24 h, loss of consciousness (LOC) not exceeding 30 min when present, and a Glasgow Coma Scale (GCS) score between 13 and 15. Current treatment options include prescribed rest followed by a gradual return to physical activity, medication management for symptoms with cognitive behavioral therapy, or vestibular physical therapy. Notably, several of these diagnostic criteria overlap with known poor prognostic indicators. These prognostic factors can be grouped into three categories: injury-related factors (LOC, positive imaging findings, history of prior concussions, and high symptom burden); patient-related factors (demographic characteristics and psychiatric history); and contextual psychosocial factors.

## Full-text entities

- **Genes:** S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, UCHL1 (ubiquitin C-terminal hydrolase L1) [NCBI Gene 7345] {aka HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}
- **Diseases:** tension-like (MESH:D018781), chronic migraines (MESH:D008881), MOH (MESH:D051271), skull fractures (MESH:D012887), aggressiveness (MESH:D010554), agitation (MESH:D011595), concussive injury (MESH:D056104), amnestic and disorientation (MESH:D003221), PTSD (MESH:D013313), brain degeneration (MESH:D001927), hemorrhagic axonal injury (MESH:D020145), Post-concussive symptoms (MESH:D038223), dementia (MESH:D003704), vomiting (MESH:D014839), loss of attention (MESH:D001289), MDD (MESH:D003865), Inflammatory (MESH:D007249), TBI (MESH:D000070642), anxiety (MESH:D001007), head injury (MESH:D006259), intraventricular (MESH:D006345), memory impairment (MESH:D008569), cognitive and somatic symptoms (MESH:D000071896), neuronal injury (MESH:D009410), structural injury (MESH:D020914), Coma (MESH:D003128), fatigue (MESH:D005221), brain fog (MESH:D005222), brain damage (MESH:D001925), chronic pain (MESH:D059350), intracranial complications (MESH:D008107), falls (MESH:C537863), depression (MESH:D003866), intracranial hemorrhage (MESH:D020300), brain injury (MESH:D001930), contusion (MESH:D003288), injuries (MESH:D014947), Subarachnoid hemorrhage (MESH:D013345), dizziness (MESH:D004244), tingling (MESH:D010292), white matter hyperintensities (MESH:D056784), subdural hematoma (MESH:D006408), nausea (MESH:D009325), hemorrhage (MESH:D006470), CT (MESH:C000719218), intraventricular hemorrhage (MESH:D000074042), Concussion (MESH:D001924), behavioral dysregulation (MESH:D021081), inattentiveness (MESH:D001308), CTE (MESH:D000070627), neurodegeneration (MESH:D019636), LOC (MESH:D014474), paranoia (MESH:D010259), headache (MESH:D006261), numbness (MESH:D006987), PTA (MESH:D004834), VPT (MESH:D016609), cognitive and memory deficits (MESH:D003072), mood (MESH:D019964), Sleep disturbances (MESH:D012893)
- **Chemicals:** aspirin (MESH:D001241), amitriptyline (MESH:D000639), glutamate (MESH:D018698), caffeine (MESH:D002110), serotonin (MESH:D012701), mirtazapine (MESH:D000078785), Melatonin (MESH:D008550), venlafaxine (MESH:D000069470), VPT (-), calcium (MESH:D002118), acetaminophen (MESH:D000082)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023580/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13023580/full.md

## References

81 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023580/full.md

---
Source: https://tomesphere.com/paper/PMC13023580